The New England journal of medicine, 2017-09, Vol.377 (12), p.1119-1131
- Ridker, Paul M
- Everett, Brendan M
- Thuren, Tom
- MacFadyen, Jean G
- Chang, William H
- Ballantyne, Christie
- Fonseca, Francisco
- Nicolau, Jose
- Koenig, Wolfgang
- Anker, Stefan D
- Kastelein, John J.P
- Cornel, Jan H
- Pais, Prem
- Pella, Daniel
- Genest, Jacques
- Cifkova, Renata
- Lorenzatti, Alberto
- Forster, Tamas
- Kobalava, Zhanna
- Vida-Simiti, Luminita
- Flather, Marcus
- Shimokawa, Hiroaki
- Ogawa, Hisao
- Dellborg, Mikael
- Rossi, Paulo R.F
- Troquay, Roland P.T
- Libby, Peter
- Glynn, Robert J
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Ridker, Paul M
- Everett, Brendan M
- Thuren, Tom
- MacFadyen, Jean G
- Chang, William H
- Ballantyne, Christie
- Fonseca, Francisco
- Nicolau, Jose
- Koenig, Wolfgang
- Anker, Stefan D
- Kastelein, John J.P
- Cornel, Jan H
- Pais, Prem
- Pella, Daniel
- Genest, Jacques
- Cifkova, Renata
- Lorenzatti, Alberto
- Forster, Tamas
- Kobalava, Zhanna
- Vida-Simiti, Luminita
- Flather, Marcus
- Shimokawa, Hiroaki
- Ogawa, Hisao
- Dellborg, Mikael
- Rossi, Paulo R.F
- Troquay, Roland P.T
- Libby, Peter
- Glynn, Robert J
- Titel
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- Ist Teil von
- The New England journal of medicine, 2017-09, Vol.377 (12), p.1119-1131
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The 150-mg dose, but not the 50-mg or 300-mg dose, led to a lower incidence of recurrent cardiovascular events.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1707914Titel-ID: cdi_swepub_primary_oai_gup_ub_gu_se_259619
- Format
- –
- Schlagworte
- Aged, Angina, Angina pectoris, Anti-Inflammatory Agents - administration & dosage, Anti-Inflammatory Agents - adverse effects, Antibodies, Monoclonal - administration & dosage, Antibodies, Monoclonal - adverse effects, Arteriosclerosis, Atherosclerosis, Atherosclerosis - blood, Atherosclerosis - drug therapy, C-reactive protein, C-Reactive Protein - metabolism, Cardiovascular disease, Cardiovascular diseases, Cardiovascular Diseases - epidemiology, Cardiovascular Diseases - mortality, Cerebral infarction, Cholesterol, Clinical Medicine, Clinical trials, Cytokines, Disease prevention, Dose-Response Relationship, Drug, Double-Blind Method, Double-blind studies, Drug dosages, Drug therapy, Female, Health risk assessment, Heart attacks, Humans, Incidence, Infection - etiology, Inflammation, Innate immunity, Interleukin-1beta - antagonists & inhibitors, Interleukin-1beta - immunology, Klinisk medicin, Lipids - blood, Male, Middle Aged, Monoclonal antibodies, Myocardial infarction, Myocardial Infarction - drug therapy, Myocardial Infarction - prevention & control, Neutropenia - chemically induced, Proteins, Secondary Prevention, Stroke, Stroke - prevention & control, Thrombosis